Latest News
DECISION TO RECOMMEND MAVENCLAD®
20th August 2018
The Pharmaceutical Benefits Advisory Committee (PBAC) announced the recommendation for listing on the Pharmaceutical Benefits Scheme (PBS) of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS), subject to final approval by the Federal Health Minister.
Read More
LOCAL BIOMARKER RESEARCH A KEY PART OF MSWA’S RECORD $3 MILLION INVESTMENT
14th August 2018
For the thousands of Western Australians living with multiple sclerosis (MS) new treatments offer hope and relief. But for clinicians it’s often challenging to know if a particular treatment is working.
Read More
World MS Day, bringing us closer
30th May 2018
Fatigue and blurred vision were the first signs for Chloe Baker that something wasn’t right. In 2017, the 31-year-old moved home from New Zealand to be with her family and focus on her health. An eye test led to an MRI, and then a diagnosis of multiple sclerosis (MS).
Read More
SUBSEQUENT DECISION NOT TO RECOMMEND MAVENCLAD®
23rd April 2018
The Pharmaceutical Benefits Advisory Committee (PBAC) have announced they have not recommended the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).
